SANA Stock Analysis: Sana Biotechnology | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 977m USD | 12M Return: 18.5% | US7995661045 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 7.98M
Qual. Beats: 0
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 5.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Sana Biotechnology (NASDAQ: SANA) is a Seattle-based clinical-stage biotechnology company developing engineered cell therapies, with operations focused in the United States. The company works across both ex vivo and in vivo cell engineering platforms, targeting areas of unmet need such as type 1 diabetes, B cell mediated autoimmune diseases, and oncology. Its pipeline includes UP421 (a HIP-modified allogeneic islet cell therapy in Phase 1 for type 1 diabetes), SC451 (a stem cell-derived pancreatic islet cell therapy in preclinical development), and the SG293/SG299 fusosome candidates aimed at B cell hematologic malignancies and autoimmune indications.
Sanas business model relies on a combination of internal R&D and external partnerships to advance its pipeline, including an option and license agreement with Beam Therapeutics for CRISPR Cas12b editing technology, a license agreement with Harvard College for hypoimmune-modified cell IP, and a strategic collaboration with Mayo Clinic supporting the SC451 program. Originally incorporated in 2018 as FD Therapeutics, the company rebranded later that year and went public on NASDAQ in early 2021. As a small-cap, pre-revenue biotech in the cell therapy subsector, Sana depends on capital markets and collaboration income to fund its multi-year clinical development activities.
- UP421 phase 1 diabetes trial data readout expected
- Cash runway concerns as R&D spending exceeds $500M annually
- Beam Therapeutics partnership advances gene-edited cell therapy pipeline
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.36 > 0.02 and ΔFCF/TA 14.49 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.35 > 3% & CFO -132.6m > Net Income -242.0m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 1.29 > 1.5 & < 3 |
| Outstanding Shares: last quarter (276.9m) vs 12m ago 16.53% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 3.43%; Δ -3.43% > 0%) |
| Interest Coverage Ratio: -4.57 > 6 (EBIT TTM -198.6m / Interest Expense TTM 43.4m) |
| A: 0.07 (Total Current Assets 111.7m - Total Current Liabilities 86.3m) / Total Assets 373.6m |
| B: -5.08 (Retained Earnings -1.90b / Total Assets 373.6m) |
| C: -0.48 (EBIT TTM -198.6m / Avg Total Assets 409.5m) |
| D: 0.47 (Book Value of Equity 119.2m / Total Liabilities 254.4m) |
| Altman-Z'' = -18.87 = D |
As of August 09, 2026, the stock is trading at USD 3.52 with a total of 2,150,866 shares traded. Over the past week, the price has changed by +12.46%, over one month by -14.56%, over three months by +0.57% and over the past year by +18.52%.
Current recommended Stop Loss: 3.20 (which is 9.1% or 1.5 ATR below the current price).
Sana Biotechnology has received a consensus analysts rating of 4.38. Therefore, it is recommended to buy SANA.
- StrongBuy: 4
- Buy: 3
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 8.6 | 143.5% |
P/B = 7.305
Revenue TTM = 0.0 USD
EBIT TTM = -198.6m USD
EBITDA TTM = -187.1m USD
Long Term Debt = 60.5m USD (estimated: total debt 75.3m - short term 14.9m)
Short Term Debt = 14.9m USD (from shortTermDebt, last quarter)
Debt = 75.3m USD (from shortLongTermDebtTotal, last quarter) (leases 75.3m already included)
Net Debt = -25.8m USD (calculated: Debt 75.3m - CCE 101.1m)
Enterprise Value = 951.0m USD (976.8m + Debt 75.3m - CCE 101.1m)
Interest Coverage Ratio = -4.57 (Ebit TTM -198.6m / Interest Expense TTM 43.4m)
EV/FCF = -7.12x (Enterprise Value 951.0m / FCF TTM -133.6m)
FCF Yield = -14.05% (FCF TTM -133.6m / Enterprise Value 951.0m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 12.8m) / Revenue TTM)
Tobins Q-Ratio = 2.55 (Enterprise Value 951.0m / Total Assets 373.6m)
Interest Expense / Debt = 57.66% (Interest Expense 43.4m / Debt 75.3m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -156.9m (EBIT -198.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.29 (Total Current Assets 111.7m / Total Current Liabilities 86.3m)
Debt / Equity = 0.63 (Debt 75.3m / totalStockholderEquity, last quarter 119.2m)
Debt / EBITDA = 0.14 (negative EBITDA) (Net Debt -25.8m / EBITDA -187.1m)
Debt / FCF = 0.19 (negative FCF - burning cash) (Net Debt -25.8m / FCF TTM -133.6m)
Total Stockholder Equity = 149.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -59.09% (Net Income -242.0m / Total Assets 373.6m)
RoE = -161.9% (Net Income TTM -242.0m / Total Stockholder Equity 149.5m)
RoCE = -94.57% (EBIT -198.6m / Capital Employed (Equity 149.5m + L.T.Debt 60.5m))
RoIC = -51.90% (negative operating profit) (NOPAT -156.9m / Invested Capital 302.2m)
WACC = 11.35% (E(976.8m)/V(1.05b) * Re(12.23%) + (debt cost/tax rate unavailable))
Discount Rate = 12.23% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 92.49 | Cagr: 16.24%
[DCF] Fair Price = unknown (Cash Flow -133.6m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.19 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.12 | Chg30d=-0.42% | Revisions=+0% | Analysts=4
EPS next Quarter (2026-09-30): EPS=-0.12 | Chg30d=+1.38% | Revisions=+0% | Analysts=4
EPS current Year (2026-12-31): EPS=-0.58 | Chg30d=+2.67% | Revisions=+25% | GrowthEPS=+13.5% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-0.52 | Chg30d=+3.03% | Revisions=+25% | GrowthEPS=+9.9% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: +40% (up=2, down=0)